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Solari E, Marcozzi C, Bistoletti M, Baj A, Giaroni C, Negrini
D, Moriondo A. TRPV4 channels’ dominant role in the tempera-
ture modulation of intrinsic contractility and lymph flow of rat
diaphragmatic lymphatics. Am J Physiol Heart Circ Physiol 319:
H507–H518, 2020. First published July 24, 2020; doi:10.1152/
ajpheart.00175.2020.—The lymphatic system drains and propels
lymph by extrinsic and intrinsic mechanisms. Intrinsic propulsion
depends upon spontaneous rhythmic contractions of lymphatic mus-
cles in the vessel walls and is critically affected by changes in the
surrounding tissue like osmolarity and temperature. Lymphatics of the
diaphragm display a steep change in contraction frequency in re-
sponse to changes in temperature, and this, in turn, affects lymph flow.
In the present work, we demonstrated in an ex vivo diaphragmatic
tissue rat model that diaphragmatic lymphatics express transient
receptor potential channels of the vanilloid 4 subfamily (TRPV4) and
that their blockade by both the nonselective antagonist Ruthenium
Red and the selective antagonist HC-067047 abolished the response of
lymphatics to temperature changes. Moreover, the selective activation
of TRPV4 channels by means of GSK1016790A mirrored the behav-
ior of vessels exposed to increasing temperatures, pointing out the
critical role played by these channels in sensing the temperature of the
lymphatic vessels’ environment and thus inducing a change in con-
traction frequency and lymph flow.
NEW & NOTEWORTHY The present work addresses the putative
receptor system that enables diaphragmatic lymphatics to change
intrinsic contraction frequency and thus lymph flow according to the
changes in temperature of the surrounding environment, showing that
this role can be sustained by TRPV4 channels alone.
intrinsic contractility; lymph flow; TRPV channels
INTRODUCTION
Lymphatic vessels drain fluid, macromolecules, and cells
from the interstitial space (37, 53), thus guaranteeing fluid
balance and, when referred to the pleural space, the proper
lung-chest wall coupling (15, 23). Lymph formation and pro-
pulsion occur by exploiting two different propulsive mecha-
nisms (5, 6, 30, 31). One of them, the so-called intrinsic
mechanism, relies on rhythmical contractions of a layer of
lymphatic muscle (LM) cells around the lymphatic endothe-
lium of collecting lymphatics (7, 28, 35, 49, 51, 55). The
spontaneous contractions of lymphatic vessels are most likely
due to either spontaneous transient depolarizations (STDs), as
in mesenteric lymphatics (47, 50), or to If-like currents typical
of cardiac pacemaker cells of the sinoatrial node mediated by
HCN channels, as reported both in mesenteric and diaphrag-
matic lymphatics (19, 29). The other mechanism, called ex-
trinsic, depends upon mechanical stresses arising in the sur-
rounding tissues and transmitted to the lymphatic vessels, such
as those occurring during cardiogenic activity (32), respiratory
movements (24), or the contraction of skeletal muscle fibers
(22, 26, 36). Depending on the location of lymphatic vessels in
different body regions, the two propulsive mechanisms can
sometimes coexist, such as occurs in the diaphragm (27).
Unlike the response observed in the medial central diaphragm,
lymphatic vessels located at the muscle periphery of diaphragm
display a complex pattern of spontaneous intrinsic contractions
(25). Those lymphatics are located in the body thermal core
and display a greater variation of intrinsic contraction fre-
quency (fc) in response to temperature changes in the 33–40°C
range compared with lymphatics located outside the thermal
core, such as those found in skin (42). This steeper response
could be due to temperature-sensitive ionic channels of the
transient receptor potential cation channels family (TRP).
TRP channels of the vanilloid subfamily comprise six mem-
bers of cation channels (V1–V6) (17), four of which serve as
temperature sensors in different tissues (1, 3). Members of the
V1, V3, and V4 subfamilies possess temperature ranges of
activation that are compatible with the physiological tempera-
ture of the body thermal core and have a high reaction rate
increase for every 10° rise in temperature (Q10 value) (11).
Thus, they are likely candidates to sense temperature changes
in diaphragmatic lymphatics.
Indeed, apart from febrile states, where temperature in-
crease and later decrease can be of 1–3° at worst, temper-
ature of muscle-associated lymphatic vessels is subjected to
the heat generated by their activity, and, for those belonging
to the muscles of the limbs, it can also decrease on the basis
of the environment temperature and the necessity to pre-
serve the body core temperature. Core temperature itself is
said to be held constant, but indeed, during exercise it may
vary from fraction of degrees or 2 to 3° due to the heat
produced by muscles in combination with the capacity of the
environment to support heat dispersion from the body (33,
44, 46). In rats, the core temperature is subjected to higher
temperature variations exacerbated by the less efficient heat
dissipation mechanism when ambient temperature increases
above 32°C, and also, circadian rhythms cause core temper-
ature to vary in a range of 1°C (34, 39).
In the present work, we present gene expression and func-
tional and immunohistochemical results obtained in an ex vivo
diaphragmatic tissue rat model to support the hypothesis thatCorrespondence: A. Moriondo (andrea.moriondo@uninsubria.it).
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TRPV4 channels may be the predominant receptors involved in
diaphragmatic lymphatic vessels’ regulation of intrinsic fre-
quency, and thus the lymph flow (Jlymph), in response to
thermal changes in the surrounding tissue.
MATERIALS AND METHODS
Surgical procedures and in vivo protocol. The whole procedure
was approved by the Animal Care and Use Ethics Committee of the
University of Insubria (OPBA) and by the Italian Ministry of Health
in accordance of the Italian D.Lgs 26/2014 (protocol 400/2015-PR).
Wistar rats coming from our in-house colony were housed in groups
of two to three littermates in standard plastic cages (Tecniplast SpA;
Buguggiate, Varese, Italy), with ad libitum access to pellet food
(standard diet) and water in a 12-h:12-h light-dark cycle.
Adult Wistar rats (both sexes, n  21; mean body weight  348  28
g) were deeply anesthetized by an intraperitoneal injection of a
ketamine (75 mg/kg body wt, Lobotor; ACME S.r.l.) and medetomi-
dine (0.5 mg/kg body wt, Domitor; Pfizer) cocktail in saline solution.
An additional half bolus was administered after 1 h while the appro-
priate level of anesthesia continuously checked, assessed by the
absence of the noxious plantar reflex of the hind paw. In vivo
fluorescent staining of the pleural diaphragmatic lymphatic network
was performed as previously described (43). Briefly, 0.8 mL of 2%
250-kDa FITC-conjugated dextrans (Ex/Em 505/515, FD250S;
Merck) in saline solution was intraperitoneally administered to deeply
anesthetized animals by using a stainless-steel injecting cannula (outer
diameter 0.8 mm) carefully inserted into the peritoneal cavity and
positioned into the subdiaphragmatic region. Dextrans or other non-
toxic high MW molecules are a standard staining medium for lym-
phatic vessels since they can only be drained by lymphatic vessels due
to the nonselectivity of the initial lymphatic vessels wall. By contrast,
blood capillaries are almost impermeant to proteins larger than 70 kDa
due to their 0.8 reflection coefficient and do not represent a draining
route for FITC-dextrans injected into the interstitium or serosal
cavities. Animals were then placed on a warmed (37°C) pad and
allowed to spontaneously breathe for 1 h to let diaphragmatic lym-
phatics drain the fluorescent tracer. At the end of the loading proce-
dure, animals were tracheotomized, and a T-shaped cannula was
inserted into the trachea; then they were paralyzed with a single bolus
of 2 mg/mL pancuronium bromide (P1918; Merck) in saline solution
administered through the jugular vein and mechanically ventilated
(Inspira; Harvard Apparatus) with room air at a tidal volume and
respiratory rate automatically set by the instrument based on animals’
body weight according to the internal parameter table programmed in
the instrument firmware by the manufacturer (page 17 of the Inspira
User Manual; Harvard Apparatus) and derived from published normal
values for rats. The chest wall was then opened to expose the pleural
diaphragmatic surface, and FITC-fluorescent filled lymphatic vessels
were visualized under a stereomicroscope (SV11, lens 1; Zeiss)
equipped with a LED epi-illuminator (custom made from Luxeonstar
high-intensity LEDs; Luxeon Star Leds), with care taken to avoid
tissue dehydration through periodical rinsing of the exposed dia-
phragm with a flush of saline heated at 37°C.
Spontaneous contracting lymphatic vessels, typically located at the
muscular diaphragmatic periphery, were video recorded in vivo at 10
fps for 5 min using a charge-coupled device (CCD) camera (Orca
ER; Hamamatsu) connected to a PC running SimplePCI Software
(Hamamatsu). From each animal, up to four or five diaphragmatic
tissue specimens containing intrinsic contracting lymphatics were
carefully excised from the costal margin to the central tendon (20).
These were subsequently used for the ex vivo experiments and placed
in petri dishes containing HEPES-buffered Tyrode’s solution [119
Mm NaCl, S7653; 5 mM KCl, P9541; 25 mM HEPES buffer, H3375;
2 mM CaCl2, 21115; 2 mM MgCl2, 63069; 33 mM D-glucose, G5767;
all products from Merck, pH  7.4; Cold Spring Harbor Protocols
(11a)] and kept at 4°C until being used. Immediately after the
diaphragmatic tissue excision, animals were euthanized by an anes-
thetic overdose injection (375 mg/kg ketamine and 2.5 mg/kg me-
detomidine).
After excision, diaphragmatic tissue specimens were pinned down
to the bottom of a perfusion chamber (RC-27D; Warner Instruments)
filled with HEPES buffer-Tyrode’s solution equilibrated with 21% O2.
The same geometry that lymphatic vessels displayed during in vivo
video recordings was maintained to avoid any mechanical stress that
could induce possible artifacts in spontaneous activity of lymphatic
vessel tracts. Specimens of contracting and noncontracting lymphatic
vessels and dorsal root ganglions (DRGs) were taken from six ran-
domly chosen animals and processed for RNA extraction and quan-
titative real-time PCR assay.
Tissue preparation for RNA extraction and quantitative real-time
PCR assay. The perfusion chamber holding the excised diaphragmatic
specimen was placed on a custom-made three-dimensional (3D)
printed support under the SV11 stereomicroscope. The tissue temper-
ature in the perfusion chamber was continuously monitored by an
implantable T thermocouple (Cole-Palmer) and maintained at
37.0  0.1°C with a PID thermostat (ITC100-VH, Inkbird, PRC),
piloting a resistive load embodied into the recording chamber. Spon-
taneous contracting lymphatics were video recorded ex vivo for 1 min
using the CCD camera, and then video data were converted to avi and
contracting sites highlighted using the “Standard Deviation Function”
(41) of ImageJ Software (National Institutes of Health; https://image-
j.nih.gov/ij/; see Ref. 38). From each animal, 1) lymphatic segments
displaying spontaneous contractions and 2) lymphatic segments of
comparable diameter not displaying intrinsic contractility were care-
fully dissected from the surrounding diaphragmatic tissue and imme-
diately frozen in dry ice, with two lymphatic sample pools obtained to
proceed with separate total RNA extraction (n  6 samples each).
Total RNA extraction from lymphatic vessels was performed using
Quick-RNA MicroPrep (R1050, Zymo Research, supplied by Euro-
Clone), following the manufacturer instructions. cDNA was then
generated by using the High Capacity cDNA Reverse Transcription
Kit (4368814; ThermoFisher) from 100 ng of total RNA, and real-
time PCR was performed on an ABI Prism 7000 instrument (Applied
Biosystems, Foster City, CA) according to the procedure described in
Ref. 4. Specific primers were designed using CLC Main workbench
software (Qiagen), as reported in Table 1, and used at a final
concentration of 500 nM to have a similar amplicon size and similar
amplification efficiency as required for applying the 2
–CT method (4).
Table 1. Oligonucleotides used in real-time PCR
experiments



















LMC -actin, lymphatic muscle -actin; TPRV1, -3, and -4, transient
receptor potential vanilloid 1, 3, and 4, respectively.
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For all genes, data were normalized on -actin and target gene
expression. TRPV mRNA levels in diaphragmatic lymphatics were
further normalized on the values obtained in DRGs. For each sample,
measurements were performed in duplicate.
Gene expression was performed for the lymphatic endothelium
marker Prox1 and the lymphatic muscle -actin (LMC -actin) to
confirm the lymphatic nature of the dissected tissue and the presence
of lymphatic muscle in the samples for -actin and for three transient
receptor potential (TRP) channels of the Vanilloid family, TRPV1,
TRPV3, and TRPV4, chosen upon their temperature range of activity.
Ex vivo functional analysis. Excised specimens lodged in the
perfusion chamber were placed onto the stage of an upright fluores-
cent microscope (BX51WI; Olympus) equipped with an epi-fluores-
cence 4 Olympus Plan APO dry objective (numerical aper-
ture  0.13) and with a black and white Watec camera (WAT-902H;
Sicom snc) connected to a PC running VirtualDub software (http://
www.virtualdub.org/), allowing 25 fps video recordings. Tissue tem-
perature was continuously monitored and recorded by means of the
implantable T thermocouple, which was placed as close as possible to
the contracting tract and maintained at  0.1°C of the desired tem-
perature with the ITC100-VH PID thermostat.
Four different sets of functional experiments were randomly per-
formed on contracting diaphragmatic lymphatics while the increasing
temperature test was performed from 35 to 39°C (see Table 2). To
avoid possible artifacts due to repeated tests, only one spontaneous
contracting vessel was video recorded for each diaphragmatic speci-
men, and a single condition at a time was tested.
In the control group (see Table 2), the temperature was raised from
the initial temperature of the perfusion chamber set up (20°C) to a
stable temperature of 35°C, and then spontaneous contractions of
FITC-filled lymphatic vessels were video recorded for 5 min in
HEPES buffer-Tyrode’s solution (baseline conditions). Afterward,
temperature was increased up to 39°C in 0.5°C steps, maintaining
the new thermal condition for 2 min to allow the whole diaphrag-
matic tissue to reach and maintain the same temperature value.
For RuR10 and RUR20 experiments (see Table 2), after 3-min
baseline acclimation at 35°C in HEPES-buffer Tyrode’s solution,
lymphatic vessels were challenged with the nonselective TRPV1–6
channel antagonist Ruthenium Red (RuR; 10 and 20 	M, 557450;
Merck; groups RuR10 and RuR20, Table 2) at 35°C for 5 min, with
lymphatic vessels’ activity always video recorded. The temperature
was successively incremented from 35 to 39°C in steps of 0.5°C,
maintaining the temperature constantly between successive steps for
2 min.
In the HC2.5 and HC5 groups (see Table 2), lymphatic vessels were
challenged with the selective TRPV4 channel blocker HC-067047
(HC, 2.5 and 5 	M, SML0143; Merck; groups HC2.5 and HC5; Table
2), while the same experimental procedure used in RuR groups was
performed. HC-067047 was dissolved in DMSO (dimethyl sulfoxide;
41639; Merck) to prepare stock solution, and aliquots were stored at

20°C until use. Aliquots were diluted in HEPES buffer-Tyrode’s
solution to achieve final concentration.
In the DMSO0.1% group, the possible effect caused by vehicle alone
(0.1% DMSO in HEPES buffer-Tyrode’s solution) was tested on
another set of lymphatic vessels with the same experimental paradigm
(Table 2).
Each set of experiments (control, RuR, HC, and DMSO0.1%
groups) was performed with 0.5°C temperature increments, thus
avoiding possible artifacts due to tissue preconditioning induced by
repeated temperature changes.
In group GSK101 (see Table 2), lymphatic vessels were video
recorded for 3 min at 35°C and then, maintaining the same tempera-
ture (35.0  0.1°C over the entire experiment), exposed to increasing
concentrations of the specific TRPV4 channel agonist GSK1016790A
(GSK101, 10–350 nM, G0798; Merck) in HEPES buffer-Tyrode’s
solution for 7 min for each dose. GSK1016790A was dissolved in
DMSO to prepare stock solutions, and aliquots, diluted in HEPES
buffer-Tyrode’s solution to achieve the desired concentration, were
stored at 
20°C until use.
In the DMSO0.01% group (see Table 2), vehicle controls (0.01%
DMSO maximum concentration in HEPES buffer-Tyrode’s solution)
were performed by using the same protocol for GSK101 experiments.
Whole mount immunostaining and image acquisition. Immediately
after dissection, diaphragmatic tissue specimens containing FITC-
filled lymphatic vessels were fixed with 4% paraformaldehyde
(158127; Merck) in PBS at room temperature for 45 min and then
rinsed in PBS and permeabilized with 100% ice-cold methanol and
subsequently with 0.5% Triton X-100 (Merck) in PBS. Thereafter,
tissue samples were incubated with blocking solution (1% BSA, 5%
goat serum in PBS) for 1 h at room temperature and then with
anti-TRPV4 primary antibody [1:60; anti-TRPV4 (extracellular) an-
tibody, ACC-124; Alomone Laboratories] (8, 40) overnight at 4°C.
After washes in PBS, specimens were incubated with a secondary goat
anti-rabbit antibody conjugated with Texas Red (1:100, sc-2780;
Santa Cruz Biotechnology) for 2 h at room temperature and then
rinsed in PBS. Overnight incubation with an anti-smooth muscle actin
primary antibody [1:50; Actin Alpha 2 Smooth Muscle Antibody
(1A4), NB600-536 Novus Biologicals] at 4°C was then followed by
rinses in PBS and a 2-h incubation with a secondary goat anti-mouse
antibody conjugated to Alexa Fluor 647 (1:100, goat anti-mouse
IgG2a; Molecular Probes) at room temperature. Eventually, tissue
samples were rinsed in PBS and mounted onto glass coverslips with
Fluoroshield with DAPI (F6057; Merck). Images were collected in the
tissue whole thickness with a confocal microscope (TCS SP5; Leica)
with 1-	m z-axis steps by using 20 dry and 40 oil objectives.
Maximum projections of adjacent fields were color-merged by using
ImageJ software (38) and manually aligned in a continuous panorama
using Adobe Photoshop Software.
Cross sections of lymphatic vessels at different sites were obtained
by using the “reslice” function of the ImageJ software on the color-
merged z-stacks.
Data analysis. Video recordings of spontaneous contractions of
diaphragmatic lymphatics were converted to black and white binary
images and were analyzed by using the “diameter” plugin (14) of the
ImageJ software to obtain diameter over time profiles highlighting
vessels’ edges displacement during intrinsic contractility.
Quantification of fc–i rate of change upon variations in tissue
temperature was performed through calculation of the Q10 values that
provide the reaction rate increase for every 10°C rise in temperature
(18) as
Q10   fcT2  fcT1T2  T1 
10
(1)
where fcT2 and fcT1 were the contraction frequencies measured at
temperature T2 and T1, respectively.
Table 2. Summary of groups used in functional experiments
Experimental Group Drug Temperature
Control None 35–39°C in 0.5 increments
RuR Ruthenium Red 35–39°C in 0.5 increments
RuR10 10 	M
RuR20 20 	M
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Diameter profiles were analyzed by Clampfit 10 Software (Molec-
ular Devices) to evaluate the lymphatic intrinsic contraction frequency
(fc; cycles/min) over a period of 1 min and measure diastolic (dd;
	m) and systolic (ds; 	m) diameters for each contraction.
Contraction amplitude (d; 	m) was computed as
d  dd  ds (2)
and expressed as percentage of dd.
Pleural diaphragmatic lymphatic vessels are ellipse shaped (25),
and the transverse to parallel diameter ratio is 0.35 (21); thus, the
changes in cross-sectional area (S; 	m2) during intrinsic contrac-
tions could be computed as
S  rd  rd  0.35  	  rs  rs  0.35  	 (3)
being rd (	m) and rs (	m) diastolic and systolic radii, respectively.
The stroke volume (SV; pl) was computed in an ideal lymphatic





being 103 the 	m3 to pl conversion factor. Then, intrinsic lymph flow
(Jlymph, nL/min) was eventually easily estimated as
Jlymph  SV  fc (5)
Statistical analysis. Data are presented as means  SE. Statistics
and data fitting were performed using SigmaPlot 10.0 Software
(Systat Software) and Graphpad PRISM (version 5). Data significance
was evaluated with unpaired Student’s t test when two groups only
were compared and one- or two-way ANOVA followed by Bonfer-
roni’s Multiple Comparison test where more groups were considered
together (i.e., data in Figs. 3–5) after data normality distribution
check. Statistical significance was set at P  0.05.
RESULTS
In ex vivo diaphragmatic intrinsically contracting lymphat-
ics (n  26), the Q10 values of fc varied between 0.4 and 30 in
the temperature range 32–40°C (Fig. 1, black circles); data
were fitted by the Gaussian peak equation
Q10  34.19  e

0.5T  36.470.85 2
with r2  0.97, centered at 36.47  0.04°C, and with a Q10
peak of 34.19  1.56.
For dermal vessels (n  5), Q10 of fc varied between 1 and
3 in the temperature range of 25–40°C and was fitted by the
following Gaussian Peak equation
Q10  2.62  e

0.5T  31.034.98 2
with r2  0.47, centered at 31.03  0.43°C, and with a Q10
peak of 2.62  0.18 (P  0.01 vs. diaphragmatic vessels,
unpaired t test; n  31).
TRPV1, -3, and -4 expression in diaphragmatic lymphatic
vessels. Prox1 gene expression (Fig. 2A) was similar in both
spontaneously contracting and not contacting vessel popula-
tions (P  0.2767, unpaired t test; n  12), confirming their
lymphatic nature, whereas the relative expression of lymphatic
muscle (LM) actin (Fig. 2A) was significantly higher (1.8
times, P  0.05, unpaired t test; n  12) in the former. As
shown in Fig. 2B, TRPV1 and TRPV3 gene expression was
similar in contracting and not contracting vessels and was not
significantly different from the transcript levels measured for
both genes in DRGs. Instead, in both populations of diaphrag-
matic lymphatics, TRPV4 expression was similar (P  0.3609,
unpaired t test; n  12) and significantly higher compared with
DRGs (P  0.01, 4.8- and 5.9-fold, respectively; n  12).
Effect of TRPV channel blocking on intrinsic lymphatic
contractions. Control vessels (mean dd 183.97  31.81 	m,
mean fc at 35°C of 10.8  1.0 cycles/min; n  10) challenged
with increasing temperature steps from 35 to 39°C showed the
typical fc sigmoidal increase (Fig. 3, gray circles) already
documented (42). Intrinsic fc data were fitted by the following
sigmoidal curve (Fig. 3, solid line):




with r2  0.99; lower fc asymptote: 10.15  0.49 cycles/
min; upper fc asymptote: 28.15  0.52 cycles/min; fc50
36.99  0.06°C (assuming fc50 as the equivalent of EC50);
Hill slope: 54.65  5.26.
When challenged with 10 	M Ruthenium Red (RuR10; Fig.
3), vessels exposed to increasing test temperatures started with
an intrinsic fc at 35°C not significantly different from control
(hollow dots; mean dd 140.95  23.20 	m, mean fc at 35°C of
11.0  1.2 cycles/min; n  17, 1-way ANOVA P  0.99),
which then was significantly lower than control fc both at 37°C
(10.4  1.3 cycles/min for RuR10 vs. 19.3  1.3 cycles/min in
control, P  0.01, 1-way ANOVA; n  17) and at 39°C
(10.4  1.4 cycles/min for RuR10 vs. 27.0  1.8 cycles/min in
control, P  0.01, 1-way ANOVA; n  17).
Data from RuR10 experiments were fitted (Fig. 3, dashed
line) by the linear regression
Fig. 1. Plot of the Q10 values of contraction frequency (fc) variation in response
to a 0.5°C change in temperature over the range of 33–40°C for diaphrag-
matic lymphatics (; n  26) and over the range of 25–40°C for dermal
vessels (Œ; n  5). Data were computed from the mean fc values from
experiments in Ref. 42 using Eq. 1 (see MATERIALS AND METHODS). Gaussian
fits of diaphragmatic vessel (solid line) and dermal vessel (dashed line) Q10
values were centered at 36.47°C and 31.03°C, respectively. Gray bar indicates
the normal range of Q10 values for simple enzymatic reactions, according to
Hille (16).
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fc  12.83  0.05  T,
with r2  0.45, fc intercept at 12.83  0.96 cycles/min, and
slope factor of 
0.05  0.03 cycles/(min ·°C).
When challenged with 20 	M Ruthenium Red (RuR20; Fig. 3,
black circles), the intrinsic fc of these diaphragmatic vessels (mean
dd 169.55  34.78 	m, mean fc at 35°C of 11.2  1.2 cycles/min;
n  6, not significantly different from control vessels at 35°C,
1-way ANOVA, P  0.99) decreased with increasing tempera-
tures and was significantly lower than in control both at 37°C
(8.8  1.0 cycles/min for RuR20 vs. 19.3  1.3 cycles/min in
control, P  0.01, 1-way ANOVA; n  16) and at 39°C
(7.3  1.2 cycles/min for RuR20 vs. 27.0  1.8 cycles/min in
control, P  0.01, 1-way ANOVA; n  16). At 39°C, fc in RuR20
was also lower, albeit not significantly, than the fc value measured
in RuR10 (7.3  1.2 cycles/min for RuR20 vs. 10.4  1.4 cycles/
min for RuR10, P  0.1273, 1-way ANOVA among the 3 groups,
P  0.27; n  13). Data from RuR20 experiments were fitted (Fig.
3, dotted line) by the following dose-response curve:




with r2  0.99; upper fc asymptote: 11.16  0.23 cycles/
min; lower fc asymptote: 7.20  0.23 cycles/min; IC50:
36.31  0.20°C; Hill slope: 
46.01  10.85.
Mean dd did not vary significantly (P  0.607, 1-way
ANOVA) among control, RuR10, and RuR20 contracting vessel
groups.
Because even the lower RuR dose (RuR10) was able to exert
a statistically significant effect, to avoid any not specific effect
due to overdosage of the drug, further comparisons between
control, RuR, and HC groups were performed considering RuR
10 	M data.
Effect of TRPV4-selective block on intrinsic lymphatic
contractions. The effect of 2.5 	M HC-067047 (group HC2.5), a
selective TRPV4 channel antagonist, on the intrinsic fc of con-
tracting diaphragmatic lymphatics (mean dd 138.57  15.54 	m,
mean fc at 35°C of 10.0  0.6 cycles/min; n  4) was described
(Fig. 4; open squares) by the linear fit (Fig. 4, dashed line)
fc  11.06  0.03  T
with r2  0.04, the fc intercept at 11.06  1.86 cycles/min, and
a slope factor of 
0.03  0.05 cycles/(min·°C). HC2.5 signif-
Fig. 2. A: relative expression of the lymphatic endothelial marker Prox1 and the lymphatic muscle (LM) actin in both contracting (Œ) and not contracting ()
lymphatics. Contracting vessels displayed significantly higher expression of LM with respect to not contracting ones evaluated by 2-way ANOVA, P  0.05;
n  6. B: relative expression of transient receptor potential vanilloid (TRPV)1, TRPV3, and TRPV4 genes in contracting (Œ) and not contracting () lymphatics
compared with the respective expression of TRPVs in dorsal root ganglions (DRGs; gray squares). TRPV4 channels were highly expressed in both contracting
and not contracting vessels; n  6 animals for all genes tested, 2-way ANOVA. *P  0.05 vs. not contracting vessels; ##P  0.01 vs. DRGs.
Fig. 3. Effect of the nonselective transient receptor potential vanilloid (TRPV)
channel antagonist Ruthenium Red (RuR) on lymphatic intrinsic contraction
frequency (fc). Control vessels (n  10; gray circles and solid line) displayed
an increase in fc with increasing temperatures from 35 to 39°C. RuR10 (n  7;
Œ and dashed line) perfusion resulted in an almost constant fc for all of the
temperatures tested, whereas RuR20 (n  6,  and dotted line) reduced fc.
**P  0.01 with respect to control at the same temperature, 1-way ANOVA;
n  17 for RuR10 and 16 for RuR20.
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icantly decreased intrinsic fc versus control both at 37°C
(10.2  0.5 cycles/min for HC2.5 vs. 19.3  1.3 cycles/min in
control, P  0.01, 1-way ANOVA; n  14) and at 39°C
(10.0  0.7 cycles/min for HC2.5 vs. 27.0  1.8 cycles/min in
control, P  0.01, 1-way ANOVA; n  14). When vessels
were challenged with 5 	M HC-067047 (group HC5; Fig. 4,
black squares; mean dd 127.95  14.90 	m, mean fc at 35°C of
10.8  0.8 cycles/min; n  3), the intrinsic fc remained almost
constant at the value displayed at 35°C according to the linear
fit (Fig. 4, dotted line)
fc  12.32  0.04  T
with r2  0.08, the fc intercept at 12.32  2.11 cycles/min, and
a slope factor of 
0.04  0.06 cycles/(min °C).
HC5 significantly reduced intrinsic fc with respect to control
both at 37°C (11.0  1.0 cycles/min for HC5 vs. 19.3  1.3
cycles/min in control, P  0.01, 1-way ANOVA; n  13) and
at 39°C (10.2  2.0 cycles/min for HC5 vs. 27.0  1.8 cycles/
min in control, P  0.01, 1-way ANOVA; n  13). Because no
significant fc differences were found between HC2.5 and HC5 at
any tested temperature (2-way ANOVA among fc of HC2.5 and
HC5 groups at every tested temperature), in the successive
experiments the lowest dose was used for comparison with
both control and RuR10 groups.
Data obtained by applying the same temperature step in-
crease protocol to vessels bathed by vehicle alone (DMSO0.1%
group, mean dd 142.22  10.36 	m; n  5) were fitted (Fig. 4,
gray triangles and solid line) by the dose-response curve




with r2  0.99; lower fc asymptote: 11.37  0.24 cycles/min;
upper fc asymptote: 27.78  0.28 cycles/min; EC50: 37.28 
0.04°C; Hill slope:63.57  4.37. No significant differences in
intrinsic fc were found between DMSO0.1% and control (Fig. 4,
dashed/dotted line, 2-way ANOVA among the 2 groups for
every temperature tested), whereas fc measured in presence of
HC2.5 and HC5 was significantly lower than the values re-
corded in DMSO0.1% both at 37°C (10.2  0.5 cycles/min for
HC2.5, 11.0  1.0 cycles/min for HC5 vs. 17.8  1.4 cycles/
min for DMSO0.1%; P  0.05, 1-way ANOVA; n  9 for
HC2.5 and P  0.01 1-way ANOVA; n  8 for HC5) and at
39°C (10.0  0.7 cycles/min for HC2.5, 10.2  2.0 cycles/min
for HC5 vs. 26.9  1.5 cycles/min for DMSO0.1%, P  0.01
1-way ANOVA; n  9 for HC2.5 and n  8 for HC5).
Mean dd did not vary significantly (P  0.536, 1-way
ANOVA) among the HC2.5, HC5, and DMSO0.1% groups.
Effect of TRPV channel blockage on contraction amplitude.
The increase in intrinsic fc recorded after increasing tempera-
ture steps from 35 to 39°C were applied in control conditions
(n  10) was associated with a decrease in lymphatic vessel
amplitude (d) from 31.1  3.2% of dd at 35°C to
17.9  3.2% of dd at 39°C. Control d data (Fig. 5A, gray
circles) were fitted (Fig. 5A, solid line) by the dose-response
curve




with r2  0.99; upper asymptote: 31.00  0.27% of dd; lower
asymptote: 17.89  0.31% of dd; IC50: 37.09  0.05°C (as-
suming the temperature as an antagonist for d); Hill slope:

79.48  7.50).
When the same temperature protocol was applied to the
RuR10 group (n  7), d decreased again (Fig. 5A; open
circles) with increasing temperatures from 29.9  4.8% of dd
at 35°C to 25.1  3.5% of dd at 39°C. However, d decrease
was lower, albeit not statistically significant, in the RuR10
group than in control group both at 37°C (27.4  4.0% of dd
for RuR10 vs. 25.0  3.3% of dd for control, P  0.6493 1-way
ANOVA; n  17) and at 39°C (25.1  3.5% of dd for RuR10
vs. 17.9  3.2% of dd for control, P  0.1561 1-way ANOVA;
n  17). RuR10 d data were fitted (Fig. 5A, dotted line) by the
dose-response curve




with r2  0.98; upper asymptote: 30.05  0.25% of dd;
lower asymptote: 24.99  0.25% of dd (significantly higher
than control, P  0.01, unpaired t test; n  17); IC50:
36.95  0.09°C; Hill slope: 
116.75  30.81.
The HC2.5 group displayed a reduction in d from
30.1  2.9% of dd at 35°C to 23.4  2.0% of dd at 39°C,
albeit one less pronounced than in control group, both
Fig. 4. Effect of the selective transient receptor potential channels of the
vanilloid 4 subfamily (TRPV4) channel blocker HC-067047 (HC) on lym-
phatic intrinsic contraction frequency (fc). Vehicle-only perfused lymphatics
(DMSO0.1%; n  5; gray triangles and solid line) displayed an increase in fc
with increasing temperatures, from 35 to 39°C, superimposable to that ob-
tained in control vessels (n  10; dashed/dotted line, plot from Fig. 3).
Addition of both HC2.5 (n  4, □ and dashed line) and HC5 (n  3;  and
dotted line) resulted in the attainment of a constant fc for every temperature
tested. **P  0.01, 1-way ANOVA with respect to control; #P  0.05, 1-way
ANOVA with respect to DMSO0.1%; ##P  0.01, 1-way ANOVA with respect
to DMSO0.1%.
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measured at 37°C (27.9  2.9% of dd for HC2.5 vs.
25.0  3.3% of dd for control, P  0.6149, 1-way ANOVA;
n  14) and at 39°C (23.4  2.0% of dd for HC2.5 vs.
17.9  3.2% of dd for control, P  0.3214, 1-way ANOVA;
n  14). HC2.5 d data (Fig. 5A, black circles) were fitted
(Fig. 5A, dashed line) by the following dose-response curve




with r2  0.99; upper asymptote: 29.84  0.21% of dd; lower
asymptote: 22.79  0.49% of dd, IC50 37.70  0.15°C; Hill
slope: 
52.37  9.03. The lower asymptote was significantly
higher than control (P  0.01, 1-way ANOVA; n  14) but
significantly lower than RuR10 (P  0.01, 1-way ANOVA;
n  11); IC50 was significantly higher than control IC50 (P
 0.01, unpaired t test; n  14); the Hill slope was not
statistically different from either to RuR10 or control group
(P  0.161 and P  0.063, 1-way ANOVA; n  11 and n 
14, respectively).
Effect of TRPV channel block on lymph flow. Lymph flow
(Jlymph) was computed for the control, RuR10, and HC2.5
groups by means of Eq. 5. In the control group (Fig. 5B, gray
circles; n  10), Jlymph increased with increasing temperature
from 2.2  0.3 nL/min at 35°C to 5.4  0.9 nL/min at 39°C.
Jlymph data were fitted (Fig. 5B, solid line) by the dose-response
curve




with r2  0.99; lower Jlymph asymptote: 2.11  0.33 nL/min;
upper Jlymph asymptote: 5.80  0.36 nL/min; EC50: 37.01 
0.18°C; Hill slope: 46.93  13.76.
On the contrary, in the RuR10 group (Fig. 5B, open
circles; n  7), Jlymph significantly decreased with increas-
ing temperatures, from 2.4  0.5 nL/min at 35°C to
1.9  0.4 nL/min at 39°C (P  0.01 vs. control, 1-way
ANOVA; n  17). Jlymph data for RuR10 were fitted (Fig.
5B, dotted line) by the dose-response curve




with r2  0.97; upper Jlymph asymptote: 2.38  0.03 nL/min;
lower Jlymph asymptote: 1.88  0.03 nL/min (significantly
lower than control at the higher temperature, P  0.01, un-
paired t test; n  17); IC50: 36.78  0.09°C; Hill slope:

211.00  72.86.
In the HC2.5 group (Fig. 5B, black circles; n  4) Jlymph
values remained almost constant at all tested temperatures,
ranging from 2.1  0.1 nL/min at 35°C to 1.8  0.2 nL/min at
39°C (significantly lower than control, P  0.05, unpaired t
test; n  14). Jlymph data for HC2.5 were fitted (Fig. 5B, dashed
line) by the dose-response curve




with r2  0.95; higher Jlymph value: 2.12  0.02 nL/min; lower
Jlymph value: 1.79  0.04 nL/min; IC50: 37.72  0.17°C; Hill
slope: 
130.48  63.98.
Lower Jlymph value was similar to RuR10 but significantly
lower than control at the higher temperature (P  0.01, 1-way
ANOVA; n  14), and the IC50 was significantly higher than
control (P  0.05, 1-way ANOVA; n  14).
Effect of TRPV4 channel activation on lymphatic intrinsic
contractility. To confirm the observed almost exclusive in-
volvement of TRPV4, we assessed the modification of fc, d,
and Jlymph due to TRPV4 activation by means of its selective
agonist GSK1016790A at a constant temperature of 35°C. In
the GSK101 group, the mean dd (148.58  21.05 	m; n  6)
did not significantly differ from the value of control vessels
(183.97  31.81 	m, P  0.4406, unpaired t test; n  16).
Increasing concentrations of GSK1016790A (from 50 nM to
350 nM) at 35°C (Fig. 6A, black diamonds) induced a concen-
Fig. 5. A: effect of the nonselective transient receptor
potential vanilloid (TRPV) channel antagonist Ruthe-
nium Red (RuR)10 (n  7; Œ and dotted line) and the
selective TRPV4 channel blocker HC2.5 (n  4;  and
dashed line) on lymphatic d, expressed as %dd. Con-
trol vessels (n  10; gray circles and solid line) dis-
played a decrease in d with increasing temperatures
from 35 to 39°C. Both RuR10 and HC2.5 perfusions
attenuated the d decrease. B: effect of RuR10 (n  7;
Œ and dotted line) and HC2.5 (n  4;  and dashed line)
on lymphatic intrinsic Jlymph. Control vessels (n  10;
gray circles and solid line) displayed a Jlymph increase
with increasing temperatures from 35 to 39°C. Both
RuR10 and HC2.5 perfusions resulted in a nonsignificant
decrease in Jlymph with respect to the values obtained at
35°C. *P  0.05, 1-way ANOVA with respect to
control; **P  0.01, 1-way ANOVA with respect to
control.
H513TRPV4 CHANNELS, TEMPERATURE, AND LYMPHATIC CONTRACTILITY
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00175.2020 • www.ajpheart.org
Downloaded from journals.physiology.org/journal/ajpheart (085.020.202.244) on September 7, 2021.
tration-dependent enhancement of fc from the basal level of
10.2  0.8 cycles/min in the absence of the drug (Fig. 6A, gray
diamonds) to 26.7  1.2 cycles/min with 350 nM GSK101.
This latter value was superimposable to that observed at 39°C
in control conditions (27.0  1.8 cycles/min, P  0.9071,
unpaired t test; n  16) and was significantly higher than fc
recorded in the presence of the vehicle-only (DMSO0.01%
group; n  4) at 35°C (fc  11.0  2.1 cycles/min in
DMSO0.01%; P  0.01, GSK101 vs. DMSO0.01% unpaired t
test; n  10). Data for fc increase due to GSK101 were fitted
(Fig. 6A, solid line) by the dose-response curve




with r2  0.99; lower fc asymptote: 10.44  0.61 cycles/min;
upper fc asymptote: 29.00  1.86 cycles/min; EC50: 142.30 
16.86 nM GSK101; Hill slope: 2.09  0.41). Both lower (P 
0.7191, unpaired t test; n  16) and upper (P  0.5949, unpaired
t test; n  16) asymptotes were not significantly different from
those obtained for the dose-response curve of control vessels
subjected to temperature increments from 35 to 39°C.
As GSK101 increased intrinsic fc to an extent similar to
control, the contractile cycle period decreased similarly in both
experimental groups, critically shortening the diastolic filling
phase. We then analyzed whether any difference could be
found in the systolic time, pointing out that increasing temper-
ature (1.10  1.00 s at 35°C and 0.78  0.08 s at 39°C; n  10
vessels), but not GSK101 perfusion at a constant 35°C
(1.01  0.09 s at GSK101: 0 nM; 1.02  0.09 at GSK101: 350
nM; n  6 vessels), altered this parameter.
GSK101 induced also a concentration-dependent reduction
of d (Fig. 6B, black diamonds) from 33.0  2.8% of dd in the
absence of the drug (Fig. 6B, gray diamonds) to 18.9  2.8%
of dd at 350 nM GSK101. This latter value was similar to the
d lower plateau displayed by control vessels exposed to 39°C
(17.9  3.2% of dd, P  0.8344, unpaired t test; n  16).
GSK101 d data were fitted (Fig. 6B, solid line) by the
dose-response curve




with r2  0.97, upper asymptote: 32.44  1.51% of dd; lower
asymptote: 17.09  3.61% of dd; IC50: 139.40  34.60 nM
GSK101; Hill slope 
2.53  1.43.
Again, also in the case of d, lower (P  0.7761, unpaired
t test; n  16) and upper (P  0.2481, unpaired t test; n  16)
asymptotes were not significantly different from those obtained
when fitting d of control vessels exposed to increasing tem-
peratures up to 39°C.
Because intrinsic fc increased and d decreased, both in a
dose-dependent manner in response to GSK101 application,
increasing concentrations of GSK101 also affected Jlymph (Fig.
6C, black diamonds). Starting from a mean Jlymph value of
2.3  0.4 nL/min in the absence of the drug (Fig. 6C, gray
diamonds), it progressively increased up to 5.3  0.9 nL/min
at 350 nM GSK101 (the same upper Jlymph previously obtained
in control vessels at 39°C, P  0.9425, unpaired t test; n  16).
Jlymph data for GSK101 experiments were fitted (Fig. 6C, solid
line) by the dose-response curve




with r2  0.99; lower Jlymph asymptote: 2.35  0.19 nL/min;
upper Jlymph asymptote: 5.72  0.48 nL/min; EC50: 131.04 
22.27 nM GSK101; Hill slope: 2.18  0.68). Both lower (P 
0.6064, unpaired t test; n  16) and upper (P  0.8949,
Fig. 6. A: effect of increasing concentrations of the selective transient receptor potential channels of the vanilloid 4 subfamily (TRPV4) agonist GSK101(50–350
nM, n  6; }) on lymphatic intrinsic contraction frequency (fc). Vessels, maintained at a constant temperature of 35°C and challenged with increasing
concentrations of GSK101, displayed an increase in fc similar to control vessels exposed to increasing temperatures. Gray diamond, intrinsic fc recorded at 35°C
in the absence of the drug. B: effect of GSK101 on intrinsic d. Increasing concentrations of GSK101 (n  6, }) induced a decrease in d similar to what has
been obtained when control vessels were exposed to increasing temperatures. Gray diamond, d measured at 35°C in the absence of the drug. C: GSK101 overall
effect on intrinsic Jlymph. Lymphatic vessels exposed to increasing concentrations of GSK101 (n  6; }) displayed an increase in Jlymph, reaching an upper plateau
superimposable to the one of control vessels challenged with increasing temperatures. Gray diamond, Jlymph mean value, computed at 35°C in the absence of
the drug.
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unpaired t test; n  16) asymptotes were not significantly
different from those obtained in control conditions.
Localization of TRPV4 channels in the lymphatic vessel
wall. To localize TRPV4 channel in the lymphatic vessel wall
(i.e., either on lymphatic muscle and/or on endothelial cells),
the distribution of TRPV4 channels along the lymphatic vessel
wall was investigated by immunofluorescent staining on whole
mount diaphragmatic specimens containing lymphatic vessels
previously in vivo (FITC-filled; see MATERIALS AND METHODS for
details). Figure 7 shows a reconstruction of a lymphatic seg-
ment obtained by aligning confocal images of several adjacent
fields, where the red signal and white dots highlight the LM
surrounding the vessel and TRPV4 channels, respectively,
whereas the green signal is due to the residual FITC-dextran
molecules adherent to the intraluminal-facing endothelial cells.
As shown in Fig. 7, boxes a= and b=, at higher magnification
(corresponding to Fig. 7, sites a and b of the main panel,
respectively), white signal seems to strongly colocalize with
FITC-dextran, as pointed out by arrowheads. Cross sections
obtained at different positions (c=–f=, corresponding to sites
c–f, respectively) highlight the LM organization surrounding
the vessel lumen and support the hypothesis that TRPV4
channels are preferentially, if not exclusively, located on the
lymphatic endothelium rather than on LM.
DISCUSSION
Q10 and the quest for the molecular sensor for temperature.
The present temperature dependence of fc in spontaneously
contracting lymphatic vessel confirms our previous obser-
vation (42) attained in both diaphragmatic and dermal lym-
phatics, although the former vessels displayed a steeper
(0.62°C·cycles
1·min
1) fc versus temperature sigmoidal rela-
tionship compared with dermal ones [2.32°C/(cycles/min)].
Based on the general notion of the temperature dependence of
biochemical reactions and considering the intrinsic fc as the
final “product” of a complex set of biochemical and mechan-
ical pathways, we thought that calculation of the Q10 value of
fc in different populations of spontaneously contracting lym-
phatics might provide some hints on the mechanisms involved
in fc modulation. Hence, in addition to the Q10 value obtained
in the present study for diaphragmatic lymphatics (Fig. 1, black
circles and solid line), we used Eq. 1 to calculate the Q10 value
in dermal lymphatics, using data from our previously published
paper (Fig. 1, open circles and dashed line). In dermal lym-
phatics, Q10 of fc (n  5) was much lower compared with
diaphragmatic ones, varying between 1 and 3 in the tempera-
ture range of 25–40°C.
Because Q10 values exceeding 2–3 likely involve active
mechanisms such as ionic channels (18), we next investigated
the expression of TRPV1, TRPV3, and TRPV4 channels (11)
in diaphragmatic lymphatics. Indeed, although both lymphatic
vessels populations displayed a temperature-dependent varia-
tion of fc, the much higher Q10 values (Fig. 1, black circles)
revealed that a possible role for active mechanisms was more
likely to occur in the diaphragmatic than in dermal vessels,
whose lower Q10 values are typical for the gating mechanism
of most ion channels (16).
TRPV channels are likely to be involved in temperature-
dependent phenomena. Indeed, some of their isoforms (V1, but
especially V3 and V4) have proven to be sensitive to temper-
ature changes in other tissues (12) and are active in the range
of temperatures experienced by tissues belonging to the ther-
Fig. 7. Whole mount immunofluorescence assay to evaluate
lymphatic muscle (LM; red signal) and transient receptor
potential channels of the vanilloid 4 subfamily (TRPV4)
channel (white signal) distribution on lymphatic vessels
displaying residual FITC-dextran (green signal) lining ves-
sel endothelium. Insets a= and b= (corresponding to sites a
and b) and cross-sections c=–f= (corresponding to sites c–f)
suggest a strong colocalization between TRPV4 channels
and lymphatic endothelium, as pointed out by arrowheads.
Scale bar, 250 	m. Inset a= and b= scale bars, 50 	m; inset
c=–f= scale bars, 25 	m.
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mal core, including diaphragmatic lymphatics (11). Hence, we
assessed the level of expression of TRPV1, TRPV3, and
TRPV4 mRNAs in the population of contracting and not
contracting diaphragmatic lymphatic vessels; TRPV2 channels
were not investigated since, because of their high-threshold
temperature of activation (52°C), they are more likely in-
volved in noxious heat sensation (10). qRT-PCR analysis
revealed that TRPV4 channel expression was five- to sixfold
higher in diaphragmatic lymphatics (Fig. 2B) than in control
DRG neurons (9, 54), whereas TRPV3 and TRPV1 channel
expression was much lower, and their transcript levels were
more similar to those observed in DRG neurons. In addition,
TRPV1 channels have a temperature threshold of 41°C,
which made them less likely to be active in the 35–39°C
physiological temperature range.
TRPV channel blockade. The temperature dependence seemed
reduced or even abolished when lymphatic vessels were treated
with TRPV antagonists. Indeed, at each dose used, the unse-
lective TRPV channel antagonist Ruthenium Red (RuR; see
Ref. 32a) completely abolished the fc increase (Fig. 3) with
increasing temperatures. To avoid TRPVs sensitization or
desensitization-related artifacts (52), the different temperatures
have always been applied in an increasing order in all of the
experiments.
The decrease in contraction frequency observed during
RuR20 perfusion might be due to an additional block (due to
the higher dose used) on TRPV1 and/or TRPV3, which are
indeed expressed in diaphragmatic lymphatics at levels com-
parable with the ones of DRGs (see Fig. 2).
However, if anything, the eventual block on TRPV3 could
be the most probable cause of the reduction of contraction
frequency given that the effect starts at 36°C, a temperature
closer to TRPV3 range of activity rather than TRPV1 one.
Similarly, when TRPV4 channels were selectively blocked
by perfusing contracting lymphatics with HC-067047 (HC), a
highly selective TRPV4 antagonist (13), fc became temperature
independent (Fig. 4), unlike what was found in control condi-
tions and in the presence of vehicle-alone (DMSO0.1%). Be-
cause the selective block of TRPV4 caused a complete abol-
ishment of fc temperature dependence, it is likely that this
specific channel isoform is the most direct and efficient among
the TRPV channel family in determining the response of
intrinsic lymphatic fc to temperature.
As already reported (42), in control conditions, when tem-
perature was raised up to 39°C, the fc increase was accompa-
nied with a decrease in contraction amplitude (d), which in
turn caused a reduction in lymphatic stroke volume (SV). This
response seemed to be a critical temperature-related mecha-
nism; indeed, when lymphatics were held at a constant tem-
perature, changes in fluid osmolarity deeply affected intrinsic fc
but not d and SV (43). At variance with the significant
flattening of fc values obtained in the presence of both drugs (as
the data in Figs. 3 and 4 show), the negative relationship
between fc and d was attenuated (Fig. 5A) but not completely
abolished when tissue specimens were perfused with either
RuR10 or HC2.5. This discrepancy might point to the fact that
the role of TRPV4 channels is predominantly linked to the
pacemaker mechanism rather than to the contraction mecha-
nism itself. The uncovering of the signaling mechanism under-
lying this effect stands beyond the scope of the present work
and would deserve a more detailed investigation at the cellular
level, which, however, cannot be carried out in our ex vivo
experimental setup. However, given that lymph flow (Jlymph) is
strictly related to both fc and contraction amplitude (Eqs. 2–5),
blockade of TRPV4, either selective or not, led to a marked
decrease of Jlymph compared with values observed in control
conditions (Fig. 5B). The net effect of the selective blockade by
HC is similar to that observed with the unselective antagonist
RuR, a further clue of the predominant role of TRPV4 among
TRPV channels in the response to temperature.
TRPV4 channel activation at constant temperature. To bet-
ter confirm the role of TRPV4 channels in shaping the response
of fc to temperature, we replicated the temperature-dependent
increase in fc in the presence of increasing concentrations of its
potent and selective agonist GSK1016790A (45) at the con-
stant temperature of 35°C to avoid possible artifacts due to the
interplay of different stimuli (i.e., either physiological, such as
temperature, or pharmacological, such as GSK101) acting on
the very same TRPV4 channels. Indeed, the response of fc to
increasing concentrations of GSK101 closely resembled the
normal response to increasing steps of temperature in control
lymphatics (Fig. 6A). Interestingly, the contraction amplitude
(Fig. 6B) varied in a fashion that closely matched the control
traces of Fig. 5A. Moreover, as additional evidence to confirm
the hypothesis that TRPV4 channels are predominantly linked
to the pacemaker mechanism, a closer analysis of how the
intrinsic fc was increased by both temperature and GSK101
showed that, whereas diastolic time decreased in both cases,
the systolic period was modified only by temperature. Never-
theless, increasing GSK101 concentrations deeply affected
Jlymph (Fig. 6C), which varied in a manner closely matching the
control response trace. Interestingly, it was possible to plot on
the same graph Jlymph values obtained in the presence of
increasing GSK101 concentrations at 35°C (Fig. 8, black
diamonds) and those obtained by increasing temperature in
Fig. 8. Comparison of Jlymph increase obtained in response to increasing
temperatures in control conditions (n  10; gray circles) and in response to
increasing concentrations of GSK101 in lymphatics held at the constant
temperature of 35°C (n  6; }), showing almost an equivalence in the 2 plots.
GSK101 dose to temperature matching was obtained by contraction frequency
(fc) vs. temperature and fc vs. GSK101 nM curves in Figs. 3 and 6A,
respectively.
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control vessels (Fig. 8, gray cicrcles) substantially obtaining
two superimposable curves. Is it worth noting that under no
circumstances did noncontracting vessels exposed to increas-
ing temperatures or GSK101 begin to display intrinsic contrac-
tions, thus indirectly confirming our previous findings that
these lymphatic vessels do not possess an adequate contracting
machinery (31).
Localization of TRPV4 channels on the lymphatic vessel
walls. Functional assays were not informative about the local-
ization of TRPV4 channels along the wall of lymphatic vessels.
Because TRPV4 channel mRNA levels were similar in con-
tracting and not contracting vessels (Fig. 2B), mRNA expres-
sion data suggested a possible endothelial localization of the
channel (Fig. 2A), as also verified with immunostaining (Fig.
7). Indeed, the TRPV4 signal was more colocalized with the
FITC signal defining the inner limits of the lymphatic vessels
(lining the endothelial cells) and to a negligible degree with the
LM actin staining, which shows their disposition on the outer
lymphatic musculature, as previously reported also in popliteal
collecting lymphatics (2). These data might imply that endo-
thelial cells might be the source of the TRPV4-derived tem-
perature signal, which is then conveyed to lymphatic muscle
cells to exert its effect.
Conclusions. The present data show that TRPV4 channels
are predominantly expressed by diaphragmatic lymphatic
vessels, and their selective block leads to the complete
absence of the temperature-dependent modulation of fc and
Jlymph normally displayed by intrinsically contracting lymphat-
ics. TRPV4-selective activation mimics the normal behavior of
lymphatics subjected to temperature changes in the physiolog-
ical range from 35 to 39°C for the thermal core, even in
stressful conditions, such as it occurs during intense exercise in
extreme conditions or fasting, opening a possible translational
implication of a pharmacological access to increase lymphatic
intrinsic pumping. Indeed, the possibility to modify fc, and thus
Jlymph, by means of selective TRPV4 channel agonist/antago-
nists may represent a useful pharmacological approach aiming
to ameliorate pathological conditions associated with mild
interstitial edema by increasing the efficiency of the lymphatic
intrinsic pump without affecting the liquid filtration process at
the blood capillaries’ endothelial layer. Moreover, whole
mount immunostaining showed a predominant localization of
TRPV4 channels on the lymphatic endothelial cells, suggesting
future research on the signaling mechanism that could link the
endothelial-derived message arising from TRPV4 channels to
the lymphatic musculature to modulate contraction frequency.
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